Donor consent for plasma use in manufacturing

Introduction

Donor consent for plasma use in manufacturing refers to the legal permission obtained from an individual before collecting and using their blood plasma for the production of medicines, therapeutic products, and other regulated biological materials. Plasma is the liquid component of blood and contains proteins such as albumin, immunoglobulins, and clotting factors. These substances are used in manufacturing essential medicines for patients suffering from immune disorders, bleeding conditions, and other serious illnesses.

Consent is important because plasma collection involves bodily intervention and the use of human biological material for purposes that may extend beyond the donor’s immediate understanding. The legal framework must therefore protect donor autonomy, privacy, dignity, and safety while ensuring that plasma-derived products meet quality and regulatory standards.

Legal framework in India

The Indian legal framework governing plasma collection and its use in manufacturing includes constitutional principles, blood-bank regulations, drug-control legislation, and ethical standards.

Article 21 of the Constitution of India protects life and personal liberty. Its interpretation includes the right to bodily integrity, privacy, and informed decision-making. Consequently, plasma collection should take place only after the donor receives adequate information and voluntarily agrees to the procedure.

The Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945, regulate the collection, processing, testing, storage, and distribution of blood and blood components. Blood centres must comply with applicable licensing requirements, technical standards, and donor-selection procedures. Plasma intended for fractionation or pharmaceutical manufacturing must also satisfy relevant quality and safety requirements.

The National Blood Policy, 2002, and applicable guidelines issued by the National Blood Transfusion Council provide an important policy framework for voluntary blood donation, donor protection, and blood safety. Consent procedures should be consistent with these standards.

Requirements of valid donor consent

Consent must be voluntary, informed, specific, and obtained before plasma collection. Donors should not be misled about the purpose of collection or pressured through financial, institutional, or social influence.

The donor should receive understandable information regarding:

The nature and purpose of plasma collection.

The intended use of plasma in manufacturing medicines or therapeutic products.

Possible physical risks and adverse reactions.

Testing procedures, including screening for transfusion-transmissible infections.

Confidentiality and handling of personal health information.

Whether the plasma may be processed, pooled, stored, or transferred to another authorised organisation.

Where plasma is collected specifically for manufacturing, the consent form should clearly explain this purpose. General consent for blood donation should not automatically be treated as sufficient permission for every unrelated future use of the collected material.

Commercial use and donor rights

Plasma may be processed by pharmaceutical manufacturers to produce medicines that are subsequently distributed commercially. The existence of commercial activity does not automatically invalidate donor consent. However, donors should not be given a misleading impression that their plasma will be used exclusively for charitable or non-commercial purposes when it is actually intended for commercial manufacturing.

The legal and ethical framework must distinguish between compensation for legitimate collection-related expenses and arrangements that may encourage unsafe or exploitative donation practices. Donors should receive accurate information about any permitted compensation or reimbursement.

Manufacturers and collection centres should also maintain traceability records, quality-control documentation, and systems for investigating adverse events. Personal information must be protected against unauthorised disclosure.

Important judicial decisions

1. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

The Supreme Court of India explained that valid medical consent must be voluntary and based on adequate information. Consent for one medical procedure does not automatically authorise a substantially different procedure. This principle is relevant to plasma collection because donors must understand the actual purpose and nature of the proposed intervention.

2. Suchita Srivastava v. Chandigarh Administration, (2009) 9 SCC 1

The Supreme Court recognised reproductive autonomy as an aspect of personal liberty under Article 21. Although the case did not concern plasma donation, its recognition of bodily autonomy supports the principle that individuals should retain control over decisions involving their bodies.

3. K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1

The Supreme Court recognised privacy as a fundamental right under Article 21. This judgment is relevant to the collection and processing of donors’ medical information, including infection-screening results and other sensitive health data.

4. Common Cause v. Union of India, (2018) 5 SCC 1

The Supreme Court discussed personal autonomy and the right to make decisions concerning medical treatment and bodily integrity. These principles support the requirement that decisions involving bodily interventions must respect individual choice.

These judgments do not directly determine plasma-manufacturing consent requirements. They provide constitutional and legal principles that can guide their interpretation.

Regulatory responsibilities and accountability

Collection centres and manufacturers must establish clear procedures to ensure that consent is properly obtained and documented. They should maintain signed consent forms, donor eligibility records, collection details, testing reports, and traceability information.

Important compliance responsibilities include:

Obtaining consent before collection.

Providing information in a language understood by the donor.

Preventing coercion and misleading representations.

Protecting donor confidentiality.

Ensuring that plasma is used only for authorised purposes.

Maintaining quality and safety standards throughout manufacturing.

If plasma is collected through an invalid or misleading consent process, the organisation may face regulatory action, civil liability, or other legal consequences depending on the nature of the violation.

Conclusion

Donor consent for plasma use in manufacturing is an essential requirement for protecting bodily autonomy, dignity, and public health. Indian constitutional principles, drug regulations, and ethical standards collectively require transparency and voluntary participation. Although Indian judicial decisions have not specifically established a comprehensive doctrine for plasma-manufacturing consent, the principles of informed consent, privacy, and bodily integrity provide a strong legal foundation. Clear consent documentation and responsible handling of plasma are therefore necessary for lawful and ethical manufacturing practices.